Latest Biotechnology News

Page 38 of 39
Bio-Gene Technology Limited has been awarded two U.S. Department of Defense grants totaling A$3 million to develop innovative insect control products targeting military and civilian markets.
Ada Torres
Ada Torres
29 Jan 2025
Neurizon Therapeutics reports encouraging 8-month interim results for its ALS drug NUZ-001, secures Orphan Medicinal Product Designation in Europe, and raises $885,000 through a share placement, maintaining a robust $14 million cash position.
Ada Torres
Ada Torres
29 Jan 2025
Actinogen Medical accelerates recruitment in its pivotal XanaMIA Alzheimer's trial while securing a strong cash position of $22.9 million, underpinning its late-stage development and commercial readiness.
Ada Torres
Ada Torres
29 Jan 2025
Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.
Ada Torres
Ada Torres
29 Jan 2025
Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.
Ada Torres
Ada Torres
24 Jan 2025
Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.
Ada Torres
Ada Torres
24 Jan 2025
Memphasys Limited marks a pivotal quarter with the completion of clinical trials for its Felix™ System, strategic market expansions in Greater China and the Middle East, and a successful capital raise to fuel growth.
Ada Torres
Ada Torres
23 Jan 2025
InhalerX Limited reported a negative cash flow for the December quarter despite securing a substantial $38.5 million funding facility aimed at advancing its clinical trials. The company has yet to draw on this facility, maintaining a cautious cash position as it progresses its drug development programs.
Ada Torres
Ada Torres
23 Jan 2025
Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.
Ada Torres
Ada Torres
23 Jan 2025
Zoono Group reports expanding global trials of its shelf-life extension technology, engaging over 40 supermarket and packaging companies, while refining its product and managing cash flow amid cautious commercial adoption.
Ada Torres
Ada Torres
22 Jan 2025
Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.
Ada Torres
Ada Torres
16 Jan 2025
Immuron has submitted its Phase 2 clinical study report for Travelan® to the FDA, revealing statistically significant immunological and microbiome benefits. The company is preparing to engage the FDA for Phase 3 trial discussions while progressing a large field study with military personnel.
Ada Torres
Ada Torres
14 Jan 2025